ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
8.39
+0.57 (7.29%)
At close: Mar 13, 2026, 4:00 PM EDT
8.40
+0.01 (0.12%)
After-hours: Mar 13, 2026, 7:59 PM EDT
ImmunityBio Market Cap
ImmunityBio has a market cap or net worth of $8.63 billion as of March 13, 2026. Its market cap has increased by 313.06% in one year.
Market Cap
8.63B
Enterprise Value
9.23B
1-Year Change
313.06%
Ranking
Category
Stock Price
$8.39
Market Cap Chart
Since March 10, 2021, ImmunityBio's market cap has decreased from $14.82B to $8.63B, a decrease of -41.81%. That is a compound annual growth rate of -10.24%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 13, 2026 | 8.63B | 342.30% |
| Dec 31, 2025 | 1.95B | 4.33% |
| Dec 31, 2024 | 1.87B | -44.23% |
| Dec 29, 2023 | 3.35B | 61.49% |
| Dec 30, 2022 | 2.08B | -14.18% |
| Dec 31, 2021 | 2.42B | -83.68% |
| Mar 10, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Madrigal Pharmaceuticals | 10.20B |
| ABIVAX Société Anonyme | 8.99B |
| Praxis Precision Medicines | 8.19B |
| Axsome Therapeutics | 7.98B |
| Bio-Techne | 7.96B |
| Vaxcyte | 7.86B |
| Arrowhead Pharmaceuticals | 7.71B |
| Nuvalent | 7.70B |